Navigation Links
ARMGO Pharma Receives $1 Million Award from MDA to Support Advancement of Rycal Compound ARM210 as a Novel Treatment for Duchenne Muscular Dystrophy
Date:4/17/2013

TARRYTOWN, N.Y. and TUCSON, Ariz., April 17, 2013 /PRNewswire/ -- ARMGO Pharma and the Muscular Dystrophy Association (MDA) today announced that $1 Million has been awarded for preclinical work in support of an Investigational New Drug (IND) application with the U.S. Food and Drug Administration (FDA) for ARM210, a novel, orally available, small-molecule Rycal drug that has potential as a treatment for Duchenne muscular dystrophy (DMD).  The funding award to ARMGO Pharma comes from MDA Venture Philanthropy (MVP), part of MDA's translational research program.

The project being advanced by ARMGO Pharma is focused on a novel class of small molecule drugs known as Rycals™ which target the Ryanodine Receptor (RyR), an intracellular calcium channel that becomes leaky in disease states including muscular dystrophy, contributing to loss of muscle strength and function.  Rycals have been shown in animal models of muscle disease to repair RyR-mediated calcium leak and thereby improve specific muscle force and exercise capacity.  ARMGO Pharma's experimental proprietary drug ARM210 has been selected by the company from its library of Rycal candidates for preclinical advancement as a potential treatment for DMD.  With its unique mechanism of action and oral delivery formulation, ARM210 has the potential to provide benefit across skeletal muscle, diaphragm and heart muscle in DMD patients regardless of genetic background, both as a mono-therapy as well as in conjunction with other treatments.

DMD is one of nine types of muscular dystrophy, a group of genetic, degenerative diseases primarily affecting voluntary muscles.  Caused by mutations in the gene that makes dystrophin, a protein that normally protects muscle cells and keeps th
'/>"/>

SOURCE ARMGO Pharma; Muscular Dystrophy Association
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. VIVUS Announces FDA Approval of Qsymia REMS Modification Allowing Access Through Certified Retail Pharmacies
2. New White Paper Details What Compounding Pharmacies Must Know to Prepare for FDA Inspections
3. Royalty Rates for Pharmaceuticals & Biotechnology: Real-Deal Information for Hundreds of Transactions
4. Omthera Pharmaceuticals, Inc. Announces Closing of Initial Public Offering
5. Avion Pharmaceuticals, LLC., announces further expansion of their Womens Health Sales Team
6. Oramed Pharmaceuticals Appoints New Chief Operating Officer and VP of Business Development
7. Valeant Pharmaceuticals To Announce 2013 First Quarter Results On May 2, 2013
8. CPhI und PharmaEvolution.com werden die Pharmaindustrie in Monats- und Jahresberichten analysieren
9. CPhI et PharmaEvolution.com sapprêtent à analyser lindustrie pharmaceutique dans des rapports mensuels et annuels
10. CPhI y PharmaEvolution.com analizarán la industria farmacéutica con informes mensuales y anuales
11. Distribution on the pharmaceutical market in Poland 2013
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/19/2014)... Avizia, Inc., a leading provider of cutting-edge ... equity financing round led by NextGen Angels along with ... will be used to continue to fuel the rapidly ... Edward Kennedy , CEO and president of Tollgrade ... Leonard Kurtzman , CFO of newBrandAnalytics, who joined the ...
(Date:8/19/2014)... MALVERN, Pa. , Aug. 19, 2014  SCILEX ... commercialization of late-stage pharmaceutical products for the treatment of ... composed of four members: Dr. Jeff Gudin , ... and Mr. Kip Vought . ... said the expertise of this board would greatly assist ...
(Date:8/19/2014)... Aug. 19, 2014 Luoxis Diagnostics, ... Inc. (NYSE MKT: AMPE), today announced an ... Meeting of the American Academy of Surgical Trauma ... in Philadelphia, Pennsylvania that ... will report results from a recently completed five-year ...
Breaking Medicine Technology:Avizia Closes Funding Round 2SCILEX Pharmaceuticals Announces Scientific Advisory Board 2SCILEX Pharmaceuticals Announces Scientific Advisory Board 3SCILEX Pharmaceuticals Announces Scientific Advisory Board 4Luoxis Announces Presentation of Positive Clinical Findings from Five-Year Clinical Study of Traumatic Brain Injury and Oxidation-Reduction Potential at 2014 American Academy of Surgical Trauma Meeting 2Luoxis Announces Presentation of Positive Clinical Findings from Five-Year Clinical Study of Traumatic Brain Injury and Oxidation-Reduction Potential at 2014 American Academy of Surgical Trauma Meeting 3
... Calif., Dec. 21 Isis Pharmaceuticals, Inc. (Nasdaq: ISIS ... payment from OncoGenex Pharmaceuticals, Inc. (Nasdaq: OGXI ) ... Pharmaceutical Industries Ltd. ( TEVA). OGX-011 is a second-generation ... a successful Phase 2 program in patients with advanced prostate ...
... , SAN DIEGO, Dec. 18 LifeVantage Corporation ... Anti-Aging Cream, science-based solutions to oxidative stress, announced today that ... other parties, Zrii, LLC. Under the terms of this agreement, ... William Farley, on the one hand, and the Company and ...
Cached Medicine Technology:Isis Pharmaceuticals to Receive $10 Million From OncoGenex' License of OGX-011 to Teva 2Isis Pharmaceuticals to Receive $10 Million From OncoGenex' License of OGX-011 to Teva 3LifeVantage Announces Settlement of Zrii Litigation 2LifeVantage Announces Settlement of Zrii Litigation 3
(Date:8/20/2014)... Los Angeles, CA (PRWEB) August 20, 2014 ... specialization and a low availability of substitutes typify the ... buyer power score of 3.1 out of 5, indicating ... buyer power suggests buyers and suppliers have an equal ... research analyst Kayley Freshman-Caffrey. , First, few substitutes exist ...
(Date:8/20/2014)... August 20, 2014 First Choice ... emergency rooms in the United States, named Richard Daniels, ... FM 685 facility. , “We are pleased to ... director of our second facility in Pflugerville,” said Dr. ... Emergency Room. , Dr. Daniels received his undergraduate ...
(Date:8/20/2014)... 20, 2014 Kowa Optimed returns after ... to debut the new SL-17 portable slit lamp. , ... white LED source controlled by an illuminated thumb wheel ... SL-17 uses commercially available AAA rechargeable and dry cell ... design requiring batteries designed specifically for the device. The ...
(Date:8/20/2014)... August 20, 2014 This agreement ... of software defined networking, high availability cloud enablement, ... of Resellers, while allowing OPEN-V to sell storageFOUNDRY’s ... pleased to work with OPEN-V on this distribution ... Hows, manager distribution channels at storageFOUNDRY. "Nautilus is ...
(Date:8/19/2014)... 2014 Midtown Dentistry in Houston, Texas, is ... All patients with cavities, or with old fillings that ... that can safely repair and restore teeth. , From now ... materials, all of which are completely amalgam free. Even though ... by the FDA for adults and children over the age ...
Breaking Medicine News(10 mins):Health News:Packaging Design Services Procurement Category Market Research Report Now Available from IBISWorld 2Health News:Packaging Design Services Procurement Category Market Research Report Now Available from IBISWorld 3Health News:Packaging Design Services Procurement Category Market Research Report Now Available from IBISWorld 4Health News:First Choice Emergency Room Announces Dr. Richard Daniels as Medical Director of the Pflugerville – FM 685 Facility 2Health News:Kowa Optimed (Booth MS13043) to Debut New Portable Slit Lamp at 2014 Vision Expo West in Las Vegas, Nevada 2Health News:storageFOUNDRY and Open-V OzoneStack Announce Bilateral Distribution Agreement 2Health News:storageFOUNDRY and Open-V OzoneStack Announce Bilateral Distribution Agreement 3Health News:Midtown Dentistry Announces It Is Now an Amalgam-Free Office 2
... Health System set out to reduce energy consumption, they weren,t ... at healthcare facilities. Instead, they,re aiming for a 20 percent ... metric tons of carbon dioxide annually that,s not being released ... the road. The La Crosse, Wis.-based health system is on ...
... a statement by UNITE HERE General President Bruce Raynor:Contrary ... press contact, today,s General Executive Board meeting ended with ... President of UNITE HERE. To be crystal clear: I ... authorized Wilhelm to discuss this issue with me.(Logo: ...
... Only two percent of hospitals nationwide receive Magnet ... Center (ANCC) has announced that Baylor University ... earned re-designation as a Magnet hospital, effective immediately. ... been designated at a Magnet hospital, and merely ...
... Pharmos Corporation (Pink Sheets: PARS) announced today that ... and warrants. At the closing, the Company issued ... an additional 18,000,000 shares of common stock for an ... of the warrants, which have a five-year term, is ...
... 2009 (BRONX, NY) Recurrent and metastatic endometrial ... They have spread to other organs and typically have ... with chemotherapy may not be able to endure more ... of Yeshiva University have shown that a combination of ...
... Exposition Park LOS ANGELES, ... of Dimes premier fundraising event that benefits all babies--those born ... 11,000 walkers are expected at this largest March for Babies ... Park, at the corner of S. Figueroa and 39th St., ...
Cached Medicine News:Health News:Innovative Program Will Help Lead Health System to Energy Independence by 2014 2Health News:Statement From UNITE HERE General President Bruce Raynor on Today's General Executive Board Meeting 2Health News:Baylor Dallas Nationally Recognized for Nursing Excellence 2Health News:Pharmos Completes Private Placement - Raises $1.8 Million 2Health News:Pharmos Completes Private Placement - Raises $1.8 Million 3Health News:New treatment shows promise against recurrent gynecologic cancers 2Health News:Farmers Insurance Joins March of Dimes March for Babies April 25, 2009 2
IBT Reference Laboratory is a national research and specialty clinical lab founded in 1983 that provides a wide range of tests and services in the area of allergy, clinical immunology and molecular b...
Marquette General Health System Reference Laboratory provides a full range of testing including, Chemistry, Hematology, Coagulation, Urinalysis, Microbiology, Cytology, Anatomic Pathology, Flow Cytom...
Headquartered in Burlington, North Carolina, LabCorp has more than 23,500 employees and offers more than 4,400 clinical tests ranging from routine blood analyses to the most sophisticated molecular d...
the LabOne Healthcare Group markets laboratory testing to physicians, patients, managed care companies, self-insured employers, wellness companies and hospitals....
Medicine Products: